Klein A, Stern M, Kaufmann H, Spalter E, Meyerson E, Hildesheim J
Cancer Detect Prev. 1983;6(1-2):107-10.
Our previous findings show that cancer patients' plasma lacks a factor (LCMEF) which is characterized by its ability to enhance lymphocytic cortisol metabolism. In the present study, using the dialysis method, we tried to evaluate the size of that factor. Plasma of healthy donors (HP) was dialyzed against water. Human lymphocytes from healthy donors were incubated with cortisol in media containing buffer (PBS) and one of the following additions: 1) dialyzate, 2) dialyzed HP (DP), 3) reconstituted HP (DP + P). The cortisol conversion rates were compared with that obtained with untreated HP and with PBS. The results showed no significant differences among the conversion rates obtained with HP, dialyzate, and reconstituted HP. Dialyzed plasma, however, showed a significantly lower rate, which was equal to that obtained with PBS. This implies that the factors are smaller than 10,000 daltons.
我们之前的研究结果表明，癌症患者的血浆缺乏一种因子（淋巴细胞皮质醇代谢增强因子，LCMEF），该因子的特点是能够增强淋巴细胞对皮质醇的代谢。在本研究中，我们使用透析法试图评估该因子的大小。将健康供体（HP）的血浆对水进行透析。来自健康供体的人淋巴细胞在含有缓冲液（PBS）以及以下添加物之一的培养基中与皮质醇一起孵育：1）透析液，2）透析后的HP（DP），3）重构的HP（DP + P）。将皮质醇转化率与未处理的HP以及PBS所获得的转化率进行比较。结果显示，HP、透析液和重构的HP所获得的转化率之间没有显著差异。然而，透析后的血浆显示出显著较低的转化率，这与PBS所获得的转化率相同。这意味着这些因子的分子量小于10,000道尔顿。
